Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

18 Dec 2018 18:00

RNS Number : 8971K
Akers Biosciences, Inc.
18 December 2018
 

December 18, 2018

 

Akers Biosciences, Inc.

 

Issue of Equity

 

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that, further to the Company's announcement on November 16, 2018, the final calculation of the fractional share entitlement round-ups resulting from the Reverse Stock Split announced on November 7, 2018 has been completed.

Accordingly, an additional 17,252 shares of common stock of no par value ("New Common Shares") have been allotted to shareholders. The Company has applied for the 17,252 New Common Shares to be admitted to trading on AIM ("Admission") and Admission is expected to occur on December 24, 2018. Following Admission, the Company's issued share capital will consist of 12,475,208 Common Shares with no Common Shares held in treasury. This figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Inquiries:

 

Akers Biosciences, Inc.

Howard R. Yeaton, Chief Executive Officer and Interim Chief Financial Officer

Tel. +1 856 848 8698

 

finnCap (UK Nominated Adviser and Broker)

Ed Frisby / Scott Mathieson (Corporate Finance)

Tel. +44 (0)20 7220 0500

 

Vigo Communications (Global Public Relations)

Ben Simons / Fiona Henson

Tel. +44 (0)20 7390 0234

Email: akers@vigocomms.com

 

About Akers Biosciences, Inc.

 

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

 

Additional information on the Company and its products can be found at www.akersbio.com.

 

Cautionary Note Regarding Forward-Looking Statements

 

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, compliance with the requirements of various regulatory agencies and certain NASDAQ Stock Market listing rules, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions, as they relate to the Company, its subsidiaries, or its management. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, performance, prospects, and opportunities to may differ materially from those set forth in, or implied by, the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEFKFDQOBDDQBD
Date   Source Headline
8th May 20181:00 pmRNSHolding(s) in Company
27th Apr 20182:05 pmRNSSecond Price Monitoring Extn
27th Apr 20182:00 pmRNSPrice Monitoring Extension
26th Apr 20187:00 amRNSDirectorate Change
13th Apr 20185:45 pmRNSIssue of Equity
12th Apr 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
6th Apr 20184:30 pmRNSIssue of Equity
3rd Apr 201811:05 amRNSFinal Results
28th Mar 20184:20 pmRNSNotice of Fiscal Year 2017 Earnings - Rescheduled
26th Mar 20187:01 amRNSDistribution Agreement with Diagnostica Stago
26th Mar 20187:00 amRNSIssue of Equity
16th Mar 20184:00 pmRNSIssue of Equity
15th Mar 20185:30 pmRNSNotice of Results
9th Mar 20186:29 pmRNSIssue of Equity
2nd Mar 20185:15 pmRNSIssue of Equity
16th Feb 20185:45 pmRNSIssue of Equity
14th Feb 20185:30 pmRNSHoldings in Company
9th Feb 20186:00 pmRNSIssue of Equity
2nd Feb 20184:42 pmRNSIssue of Equity
26th Jan 20187:00 amRNSIssue of Equity
22nd Jan 20184:27 pmRNSHoldings in Company
19th Jan 20183:35 pmRNSIssue of Equity
16th Jan 20186:20 pmRNSIssue of Equity
15th Jan 20187:00 amRNSUpdate RE Admission of Shares
12th Jan 20187:00 amRNSIssue of Equity
5th Jan 20186:29 pmRNSIssue of Equity
4th Jan 20184:45 pmRNSHoldings in Company
27th Dec 20172:01 pmRNSIssue of Equity
22nd Dec 20177:00 amRNSClosing of Public Offering
19th Dec 20177:00 amRNSIssue of Equity
18th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
15th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
14th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
11th Dec 201711:00 amRNSForm S-1 Registration Statement - Amendment
8th Dec 20173:30 pmRNSFurther IP Protection for Akers Wellness Line
1st Dec 20172:00 pmRNSForm 8K Filing
27th Nov 20177:00 amRNSForm S-1 Registration Statement
15th Nov 20177:00 amRNS3rd Quarter Results
14th Nov 20177:00 amRNSNew UK Channel for Rapid Alcohol Breathalyzer
13th Nov 20172:00 pmRNSNotice of Results
8th Nov 20171:59 pmRNSIssue of Equity
20th Oct 20177:00 amRNSPDMR Shareholding and Issue of Equity
19th Oct 20174:20 pmRNSDirector/PDMR Shareholding
13th Oct 20172:35 pmRNSWarrant Amendment and Exercise
7th Sep 20177:00 amRNSAppointment of U.S. VP of Sales & Distribution
15th Aug 20177:00 amRNSHalf-year Report
11th Aug 20177:00 amRNSIssue of Equity
8th Aug 20177:00 amRNSResult of AGM
3rd Aug 20174:30 pmRNSTrading Update and Notice of Q2 Results
20th Jul 201711:10 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.